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Abstract
Renal cell carcinoma (RCC) is characterized by organ-specific metastases. The chemokine stromal
derived factor-1 (SDF-1/CXCL12) and its receptor CXCR4 have been suggested to regulate organ-
specific metastasis in various other cancers. On this basis, we hypothesized that the biological axis
of CXCL12 via interaction with its receptor, CXCR4, is a major mechanism for RCC metastasis.
We demonstrated that CXCR4 was significantly expressed on circulating cytokeratin+ RCC cells
from patients with known metastatic RCC. We detected up-regulation of CXCR4 mRNA and
protein levels on a human RCC cell line by either knockdown of the von Hippel-Lindau (VHL)
tumor suppressor protein, or incubating the cells under hypoxic conditions. The enhanced CXCR4
expression was mediated through the interaction of the Hypoxia Inducible Factor-1α (HIF-1α) with
the promoter region of the CXCR4 gene. Furthermore, the expression of CXCR4 on human RCC
directly correlated with their metastatic ability in vivo in both heterotopic and orthotopic SCID
mouse models of human RCC. Neutralization of CXCL12 in SCID mice abrogated metastasis of
RCC to target organs expressing high levels of CXCL12; without altering tumor cell proliferation,
apoptosis, or tumor-associated angiogenesis. Therefore, our data suggest that the CXCL12/
CXCR4 biological axis plays an important role in regulating the organ-specific metastasis of RCC.
Background
Renal cell carcinoma (RCC) accounts for approximately
3% of new cancer incidence and mortality in the U.S. [1].
In general, approximately a third of the patients at time of
presentation have metastatic RCC (mRCC), and another
third that present with local disease will eventually expe-
rience recurrence and metastases with a with a median
survival of less than one year [2]. The mortality and mor-
bidity of RCC is strongly associated with its high propen-
sity to metastasize to specific organs. To explain the
specific pattern of tumor metastases, it has been demon-
strated that sites of metastases are determined not only by
the characteristics of neoplastic cells but also by the
microenvironment of the specific organ [3]. In a similar
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manner to leukocyte trafficking, the target organs for met-
astatic events express constitutive levels of chemoattract-
ants that mediate extravasation of tumor cells. Recently,
extensive studies have suggested that chemokines may
play a major role in mediating tumor metastasis [4-8].
Chemokines are a superfamily of small (8–10 kD) pro-
teins, which play a pivotal role in the regulation of leuko-
cyte trafficking and extravasation into sites of tissue
inflammation [9-13]. Different cancers are found to
express several chemokine receptors, and their corre-
sponding ligands are expressed at sites of tumor metas-
tases [6,7,14,15]. However, CXCR4 appears to be the
major chemokine receptor expressed on cancer cells
[4,5,8]. CXCR4 was originally discovered as the co-recep-
tor for lymphotropic strains of HIV [16] and CXCL12
(stromal derived factor-1, SDF-1) is its lone ligand [17].
CXCL12 has been found to be secreted by bone marrow
stromal cells and is important during embryogenesis for
the colonization of bone marrow by HSC [18]. It is also
essential in adult life for retention/homing of HSC [19].
Both CXCL12-/- and CXCR4-/- mice die in utero with defects
in heart, brain and large vessel development [20-24]. The
role of CXCL12/CXCR4 axis in organ-specific metastasis
was initially suggested in breast cancer [6]. Since then,
CXCR4 expression has been reported in at least twenty
three epithelial, mesenchymal and hematopoietic cancers,
suggesting the importance of this ligand/receptor axis, in
general in tumor metastasis [4,5,8]. In addition, studies
have also suggested that CXCL12/CXCR4 may indirectly
promote tumor metastases by mediating proliferation of
tumor cells and enhancing tumor-associated angiogenesis
[25-32].
While increasing evidence has suggested the pivotal role
of CXCL12/CXCR4 biological axis in tumor metastasis,
the specific mechanisms regulating CXCR4 expression in
different tumors are poorly understood. Recently,
Hypoxia Inducible Factor-1α (HIF-1α) has been found to
be a critical transcription factor for gene expression of
CXCR4 in RCC [33,34]. Moreover, von Hippel-Lindau
tumor suppressor gene (VHL), the most common
mutated gene in RCC, was found to negatively regulate
the expression of CXCR4, owing to its capacity to target
HIF-1α for degradation under normoxic conditions
[33,34]. More recently, we showed that both EGF and
hypoxia can induce CXCR4 expression in non-small cell
lung cancer (NSCLC) cells via the VHL/HIF-1α axis and
this process is regulated by both the PI3-kinase/PTEN/
AKT/mTor pathway and hypoxia [35]. These findings led
to the hypothesis that CXCR4 is a biomarker that predicts
the metastatic potential of RCC, and that the CXCL12/
CXCR4 biological axis is regulated by VHL/HIF-1α in RCC
and is a major mechanism for trafficking of RCC to meta-
static sites.
In an effort to address the potential role of CXCR4 as a
biomarker for predicting the metastatic potential of RCC,
we first measured CXCR4 expression on circulating cytok-
eratin+ cells in patients with mRCC, and found signifi-
cantly increased levels of cytokeratin+ cells that co-
expressed CXCR4, as compared to normal human sub-
jects. CXCR4 mRNA and protein levels were markedly up-
regulated in human RCC cell lines, in which VHL was sta-
bly knocked down via RNA interference. The expression of
CXCR4 in these cells could be further augmented in the
presence of hypoxia, and was functional in terms of chem-
otaxis in response to CXCL12. Our results further demon-
strated that the enhanced CXCR4 expression induced by
both conditions was mediated through the binding of
HIF-1α to the CXCR4 promoter region, which lead to
increased transcription of the CXCR4 gene. The expres-
sion of CXCR4 on human RCC correlated with their met-
astatic ability in both heterotopic and orthotopic SCID
mouse models, and treatment with specific anti-CXCL12
antibodies markedly abrogated metastasis of RCC to tar-
get organs, expressing high levels of CXCL12, in the ortho-
topic model of RCC without significant changes in tumor
cell proliferation, tumor cell apoptosis, or tumor-associ-
ated angiogenesis of the primary tumor. The findings of
this study support the notion that the CXCL12/CXCR4
biological axis plays a critical role in regulating organ-spe-
cific metastasis of RCC.
Results
CXCR4 is significantly expressed on circulating cytokeratin 
positive cells in patients with mRCC
Recent studies have shown that the CXCL12/CXCR4 bio-
logical axis is important in trafficking malignant cells in
an organ-specific manner [4,5,8], and that hypoxia
through HIF-1α/VHL appears to modulate the expression
of CXCR4 on malignant cells [33-35]. However, CXCR4
has not been previously shown to be expressed on meta-
static circulating mRCC cells. We therefore hypothesized
that CXCR4 would be expressed on a circulating popula-
tion of cells compatible with mRCC. We enrolled 21
patients with mRCC into a pilot study, as well as three
normal volunteer control subjects, and obtained 10 mls of
heparinized blood and isolated the buffy-coat cells for
FACS analysis of cytokeratin and dual color analysis of
CXCR4 expression. As shown in Fig. 1, we found a marked
increase in cytokeratin positive cells in the circulation of
patients with mRCC, as compared to normal control sub-
jects. A large variation in the number of circulating cytok-
eratin+ cells and cytokeratin+ CXCR4+ cells could be
observed in mRCC patients, with more than 50-fold dif-
ference between the patient with smallest number of
stained cells and the patient with largest number of these
cells. When the cytokeratin positive cells from patients
with mRCC were examined for expression of CXCR4, >
90% were found to be CXCR4 positive. In the three nor-Molecular Cancer 2006, 5:56 http://www.molecular-cancer.com/content/5/1/56
Page 3 of 14
(page number not for citation purposes)
mal control subjects, the levels of cytokeratin positive
cells, although detectable, were extremely low and com-
patible with the presence of cytokeratin+ cells in normal
subjects [36,37]. These findings support the notion that
the majority of potential circulating RCC cells express
CXCR4, and may serve as a foundation for further studies
to define whether the presence and magnitude of circulat-
ing mRCC cells are prognostic in patients with RCC.
Hypoxia plays a significant role in the regulation of 
CXCR4 on human RCC
Recently, the expression of CXCR4 on RCC and NSCLC
tumor cells was shown to be regulated by hypoxia and the
VHL/HIF-1α pathway [33-35]. To further characterize the
role of hypoxia and/or VHL/HIF-1α in the regulation of
the expression of CXCR4 on RCC cells and to determine
whether this chemokine receptor is a critical factor for
promoting RCC metastases, we next exposed SN12C-P,
SN12C-VC and SN12C-VHL-KD cells to normoxia or
hypoxia for 2, 4, 8, and 24 hours and isolated mRNA and
protein for quantitative TaqMan RT-PCR and Western blot
analysis of CXCR4, respectively. As shown in Fig 2A,
SN12C-VHL-KD cells demonstrated a marked increase in
CXCR4 gene expression under both normoxic and
hypoxic conditions, as compared to SN12C-VC. Similar
results were found when comparing the SN12C-VHL-KD
to SN12C-P (data not shown). Total cellular levels of
CXCR4 protein paralleled the expression of mRNA in
SN12C-VHL-KD cells with significantly higher levels of
CXCR4 protein found under both conditions of normoxia
and hypoxia, as compared to either SN12C-P or SN12C-
VC cell lines (Fig. 2B). These latter two cell lines demon-
strated markedly increased CXCR4 protein levels only
under hypoxic conditions (Fig. 2B). CXCR4 cell surface
expression was seen by FACS analysis and correlated with
the results obtained from Western blot analysis (data not
shown).
VHL knockdown and hypoxia increase the chemotactic 
responsiveness of RCC cells to CXCL12
After confirming the role of the HIF-1α/VHL axis in the
up-regulation of CXCR4 mRNA and protein expression,
we assessed whether this led to functional differences in
migration in response to the CXCR4 ligand, CXCL12.
SN12C-P, SN12C-VC, and SN12C-VHL-KD cells were
exposed to either normoxia or preconditioned with
hypoxia for 24 hours followed by analysis of chemotaxis
in response to CXCL12. SN12C-VHL-KD cells demon-
strated a dose-dependent increase in chemotaxis in
response to CXCL12 under both conditions of normoxia
and hypoxia (Fig. 3). Hypoxia preconditioning of the
SN12C-VC and SN12C-P cells also resulted in a dose-
dependent increase in chemotactic activity (Fig. 3 and
data not shown). The levels of chemotactic activities of
SN12C-VC were not significantly different from those of
SN12C-P cells under either normoxic or hypoxic condi-
tions (data not shown). These results confirmed that the
loss of function of VHL results in augmented chemotactic
activity in response to CXCL12. Moreover, in cells with
functional VHL, hypoxia plays a role to increase this
response.
VHL knockdown and hypoxia activate HIF-1α expression 
in human RCC cells and promote HIF-1-mediated 
transcription of the CXCR4 promoter
Having established that VHL knockdown and/or hypoxia
are capable of up-regulating CXCR4 expression in SN12C
cells, we next wanted to examine the underlying mecha-
nism that mediates this effect. It has been reported that
the VHL tumor suppressor protein negatively regulates
CXCR4 expression owing to its capacity to target HIF-1α
for degradation under normoxic conditions, and that
CXCR4 induction by hypoxia is dependent on the transac-
tivation of HIF-1α [33-35]. Thus, we exposed SN12C-VC
and SN12C-VHL-KD cells to either normoxia or hypoxia
for the times indicated and then examined intranuclear
HIF-1α expression by Western analysis (Fig. 4A). Under
normoxic conditions little or no intranuclear expression
of HIF-1α was observed in SN12C-VC cells, whereas the
expression of HIF-1α was detectable in SN12C-VHL-KD
cells within 2 hours. Under hypoxic conditions, strong
intranuclear expression of HIF-1α was observed in both
SN12C-VC and SN12C-VHL-KD cells. The expression of
HIF-1α in SN12C-VHL-KD cells, however, could be
Expression of CXCR4 on circulating pan-cytokeratin positive  cells in patients with mRCC as determined by FACS analysis Figure 1
Expression of CXCR4 on circulating pan-cytokeratin positive 
cells in patients with mRCC as determined by FACS analysis. 
Cells isolated from the buffy coat of mRCC patients were 
stained with pan-cytokeratin (dark-colored boxes) or stained 
with both pan-cytokeratin and CXCR4 for dual color analysis 
(light-colored boxes). Specimens from three normal human 
subjects were included as controls.
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observed as early as 2 hours after exposure to hypoxia
when HIF-1α was barely detectable in SN12C-VC cells;
and remained elevated at 8 to 24 hours after exposure to
hypoxia, when HIF-1α elevation was no longer detected
in SN12C-VC cells (Fig. 4A).
To further verify that HIF-1α contributed to the transcrip-
tion and up-regulation of CXCR4 gene expression, we
transfected the SN12C-VC and SN12C-VHL-KD cells with
a luciferase reporter construct containing a 2.6-kb frag-
ment of the CXCR4 promoter as well as either a random
control GFP cDNA or HIF-1α cDNA as previously
described [35] (Fig. 4B). Transfected cells were then
exposed to either hypoxic or normoxic conditions. Under
these conditions significant transactivation of the CXCR4
promoter was observed in those cells receiving the HIF-1α
cDNA but not the GFP cDNA, and those cells exposed to
hypoxia but not normoxia (Fig. 4B). Furthermore, signifi-
cant activation of CXCR4 promoter could be detected in
SN12C-VHL-KD cells even under normoxic conditions
Hypoxia and VHL knockdown enhance CXCR4 expression Figure 2
Hypoxia and VHL knockdown enhance CXCR4 expression. (A). SN12C-VHL-KD cells were serum-starved and exposed to 
either normoxia or hypoxia (94% N2, 5% CO2 and 1% O2) for the times indicated. Changes in gene expression were then 
determined by real-time quantitative PCR. Fold induction represents increases in CXCR4 expression in SN12C-VHL-KD cells 
compared to SN12C cells transfected with vector control (SN12C-VC). (B). SN12C-P, SN12C-VC and SN12C-VHL-KD cells 
were treated with either normoxia or hypoxia as described in (A) for the times indicated and then subjected to Western anal-
ysis to examine changes in CXCR4 protein levels.
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and in the absence of HIF-1α cDNA transfection. This acti-
vation was further enhanced by either hypoxic precondi-
tioning or transfection with HIF-1α cDNA (Fig. 4B).
Next, to obtain direct evidence for the physical interaction
between HIF-1α and the CXCR4 promoter, we performed
a chromatin immunoprecipitation assay to determine
whether VHL knockdown and/or hypoxia promoted the
binding of the HIF-1α transcription factor to its cognate
DNA binding motif on the CXCR4 promoter region (Fig.
4C). We exposed SN12C-VC and SN12C-VHL-KD cells to
normoxia or hypoxia for 4 hours and then prepared, pre-
cleared and sonicated chromatin solutions for analysis.
Our results indicate that under normoxic conditions there
is little or no inducible binding of HIF-1α to the CXCR4
promoter in SN12C-VC cells, whereas a 4-hour exposure
to hypoxia mediated a much stronger interaction between
HIF-1α and the CXCR4 promoter in these cells (Fig. 4C).
In contrast, significant recruitment of HIF-1α to the
CXCR4 promoter could be observed in SN12C-VHL-KD
cells under both normoxia and hypoxia (Fig. 4C), suggest-
ing the strong transactivation of CXCR4 promoter by the
HIF-1α transcription factor in the absence of regulation by
the tumor suppressor protein VHL.
The expression of CXCR4 on human RCC correlates with 
their metastatic ability in both heterotopic and orthotopic 
models of human RCC metastasis in SCID mice
Since our above studies demonstrated that hypoxia and
the HIF-1α/VHL axis was critical in the regulation of
CXCR4 expression and function in RCC cell lines, and our
previous study identified the major organs that express
elevated levels of CXCL12 (i.e., lungs, adrenal glands,
bone marrow, liver, and brain, as compared to the pri-
mary tumors) [7]; we next wanted to determine whether
alteration of VHL expression by knockdown could lead to
changes in metastatic behavior of RCC. Since SN12C-VC
cells demonstrated the same properties as the parental
SN12C-P cells in terms of the CXCL12/CXCR4 biological
axis in our in vitro studies (Fig. 2, Fig. 3 and data not
shown), we performed the following in vivo studies using
only SN12C-VC and SN12C-VHL-KD cells. We developed
both an orthotopic RCC tumor model using 104 SN12C-
VHL-KD or SN12C-VC cells expressing GFP directly
injected into the subcapsular region of the left kidney and
a heterotopic model using 106 SN12C-VHL-KD or SN12C-
VC cells expressing GFP injected into the flank of SCID
mice. Mice bearing tumors were sacrificed after 4 weeks,
and their major organs were harvested and processed to
assess single cell suspensions for the expression of GFP by
FACS analysis. GFP labeling of the RCC cells allowed us to
quantitatively assess the magnitude of metastatic lesions
in various organs. As shown in Fig. 5A, we found that
SN12C-VHL-KD, as compared to SN12C-VC orthotopic
tumors had a greater propensity to metastasize to specific
sites, and were found to have higher numbers of cells in
circulation/buffy coat, adrenal glands, bone marrow,
brain, liver, lung, kidney and spleen. The number of GFP
positive cells in the primary tumors, however, did not dif-
fer significantly between these two groups (data not
shown). Consistent with our findings in the orthotopic
model, we found similar results for the same human RCC
cells lines inoculated in the heterotopic position in SCID
mice (Fig. 5B).
Depletion of CXCL12 inhibits RCC metastasis
Since the expression of CXCR4 correlated to the magni-
tude of metastatic RCC cells in specific organs, we next
wanted to determine whether depletion of CXCL12 by
specific neutralizing antibodies to CXCL12 in SCID mice
bearing SN12C-VHL-KD and SN12C-VC orthotopic
tumors expressing GFP would attenuate RCC metastasis.
Having established the specificity of the anti-CXCL12
antibody [7,38], we next injected SN12C-VC or SN12C-
VHL-KD cells directly into the subcapsular region of the
left kidney of SCID mice, then treated the mice with intra-
peritoneal injections (500 µl) of either neutralizing goat
anti-CXCL12 or preimmune serum, three times per week
for 4 weeks, starting at the time of tumor cell inoculation.
At time of sacrifice, cells from different organs were iso-
lated and examined for spontaneous metastases as
assessed by FACS analysis of GFP+ tumor cells. We found
that animals bearing the human tumor cell lines treated
with neutralizing anti-CXCL12 antibodies resulted in
markedly reduced metastases to the lungs, adrenal glands,
SN12C-VC and SN12C-VHL-KD chemotaxis in the presence  of CXCL12 (1, 10 and 100 ng/ml) after 24 hours incubation  under normoxic or hypoxic conditions as described previ- ously Figure 3
SN12C-VC and SN12C-VHL-KD chemotaxis in the presence 
of CXCL12 (1, 10 and 100 ng/ml) after 24 hours incubation 
under normoxic or hypoxic conditions as described previ-
ously. Results are expressed as the number of cells that 
migrated per high-power field (HPF). Data represent the 
mean ± SEM from five HPFs.
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liver and circulation (buffy coat), as compared to control
antibody treated groups (Fig. 6). Furthermore, in the con-
text of the VHL knockdown cell line, the magnitude of
metastasis of this cell line was reduced to a similar level as
the vector control cells in the presence of anti-CXCL12
(Fig. 6).
Depletion of CXCL12 was not associated with a change in 
primary tumor vascular density, tumor cell proliferation or 
apoptosis
Having established that CXCL12 depletion significantly
impaired the metastasis of RCC to specific target organs,
we next wanted to determine whether this effect was
VHL knockdown and the condition of hypoxia induce activation of HIF-1 transcription and transactivation of the CXCR4 pro- moter Figure 4
VHL knockdown and the condition of hypoxia induce activation of HIF-1 transcription and transactivation of the CXCR4 pro-
moter. (A). SN12C-VC and SN12C-VHL-KD cells were serum-starved and exposed to either normoxia or hypoxia for the 
times indicated. Subsequently, nuclear extracts were prepared and analyzed by SDS-PAGE and Western blotting with a specific 
mouse-anti-human HIF-1α monoclonal antibody. (B). SN12C-VC and SN12C-VHL-KD cells were transfected with a reporter 
construct comprising a 2.6-kilobase fragment of the CXCR4 promoter and a separate Renilla control reporter. Cells were co-
transfected with either a control vector expressing GFP or a vector expressing HIF-1α. The transfected cells were subse-
quently exposed to either normoxia or hypoxia for 8 hours. Cell extracts were prepared and analyzed in a luminometer. Rela-
tive light units (RLU) were normalized to the Renilla control. (C). SN12C-VC and SN12C-VHL-KD cells were serum-starved 
and exposed to either normoxia or hypoxia for 4 h. ChIP assay was subsequently performed to investigate the recruitment of 
HIF-1α on the CXCR4 promoter. Precleared chromatin solutions were immunoprecipitated with either mouse anti-human 
HIF-1α monoclonal antibody or with no antibody as negative controls (N). The lower panel represents input genomic DNA 
before addition of antibody.
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mediated by CXCL12/CXCR4 biological axis on RCC
metastases, or by alterations of RCC tumor or tumor cell
biology, such as tumor-associated vascular density, or
tumor cell proliferation and/or apoptosis. Orthotopic
tumor sections of mice bearing SN12C-VC and SN12C-
VHL-KD tumors were stained using anti-Factor VIII-
related antigen antibody, anti-PCNA antibody, or TUNEL
method for the morphometric evaluation of tumor-asso-
ciated vascular density, proliferation, or apoptosis, respec-
tively. As shown in Table 1, the vascular density in
primary SN12C-VC or SN12C-VHL-KD tumors from
SCID mice as detected by Factor-VIII-related antigen stain-
ing was not significantly different in animals treated with
anti-CXCL12 antibodies, as compared to animals treated
with control antibodies. The number of SN12C-VC or
SN12C-VHL-KD tumor cells undergoing proliferation or
apoptosis, as determined by PCNA and TUNEL staining,
respectively, was not significantly different between the
anti-CXCL12 and the control antibody treated mice
(Table 1). In addition, we examined the proliferation and
apoptosis of SN12C-VC and SN12C-VHL-KD cells in vitro
in the presence of various concentrations of CXCL12 or
neutralizing anti-CXCR4 antibody by [3H]thymidine
incorporation assay and TUNEL assay, respectively. We
found that the proliferative or apoptotic properties of
SN12C-VC and SN12C-VHL-KD cells were not altered by
either stimulation or inhibition of CXCL12/CXCR4 bio-
logical axis (data not shown).
The expression of CXCR4 on human RCC cells correlates with their ability to metastasize to specific organs in SCID mice  bearing orthotopic (A) or heterotopic (B) tumors Figure 5
The expression of CXCR4 on human RCC cells correlates with their ability to metastasize to specific organs in SCID mice 
bearing orthotopic (A) or heterotopic (B) tumors. SCID mice were subjected to orthotopic or heterotopic xenoengraftment 
of either SN12C-VC or SN12C-VHL-KD cells. Six animals were included in each group. Data are expressed as the percentage 
of GFP+ cells found in each organ examined by FACS analysis. Data represent mean ± SEM.
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Discussion
RCC ranks as the 10th leading cause of cancer death [39].
The morbidity and mortality of this disease is mainly due
to its significant propensity to metastasize in an organ-
specific manner. This metastatic pattern is also shared by
various other malignancies, such as breast cancer and
NSCLC [6,7]. Müller and colleagues provided initial evi-
dence linking the CXCL12/CXCR4 biological axis to
breast cancer metastasis to specific organs [6], which was
confirmed in non-small cell lung cancer [7]. More recent
studies have suggested that CXCR4 is expressed on various
other cancer cells and its expression stimulates migration
of cancer cells towards a CXCL12 gradient established in
specific target organs [4,5,8]. Furthermore, elevated
CXCR4 expression was detected in several human RCC
cell lines and tumor samples, while only minimal CXCR4
expression was detected in normal kidney tissues [40].
While these findings suggested that the CXCL12/CXCR4
biological axis may be a critical determinant for the meta-
static potential of RCC, studies demonstrating a direct link
of CXCR4 expression and metastatic potential remained
to be elucidated in response to organ-specific expression
of CXCL12.
Given that CXCR4 mediates the trafficking of breast and
non-small cell lung cancer cells in an organ-specific man-
ner [4,5,8], we hypothesized that there would be an
increase in the number of RCC cells in circulation in
Neutralization of CXCL12 in animals bearing orthotopic human RCC tumors resulted in attenuated metastasis to specific  organs Figure 6
Neutralization of CXCL12 in animals bearing orthotopic human RCC tumors resulted in attenuated metastasis to specific 
organs. SCID mice bearing orthotopic xenoengraftment of either SN12C-VC or SN12C-VHL-KD cells were subjected to 
intraperitoneal injection of anti-CXCL12 antibodies or preimmune serum as a control. Six animals were included in each treat-
ment group. Data are expressed as the percentage of GFP+ cells found in each organ examined by FACS analysis. Data repre-
sent mean ± SEM.
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patients with mRCC, and that these cells would express
CXCR4. Upon analysis of buffy coats from patients with
known mRCC, we indeed found that there was a marked
increase in the number of cytokeratin+ cells in circulation
compared to normal subjects, suggesting that these cells
were comparable with circulating malignant cells. The
number of circulating cytokeratin+ cells varied greatly
among patients, however in most cases circulating cytok-
eratin+ cells made up a significant portion of total blood
cell counts (data not shown), indicative of disease pro-
gression [41,42]. The low levels of cytokeratin+ cells in
normal subjects may be due to expression of cytokeratin
by bone marrow-derived stem cell subpopulations, which
has previously been described [36,37,43]. When the
cytokeratin+ cells from patients with mRCC were exam-
ined for expression of CXCR4, > 90% of them were found
to be CXCR4 positive. These findings suggest that CXCR4
is a predominant biomarker on cytokeratin+ cells in the
circulation of patients with mRCC and the presence of
CXCR4 expression on these cells may directly correlate
with mRCC. Furthermore, these studies may support
future clinical trials that use the presence and magnitude
of cytokeratin+ CXCR4+ cells as a prognostic biomarker in
patients with RCC.
Recent studies have suggested that hypoxia, particularly
HIF-1α, regulates the expression of CXCR4 in RCC
[33,34,44]. These studies further suggest that the loss or
functional inactivation of the protein product of VHL, a
tumor suppressor gene commonly mutated in clear cell
RCC, results in persistent activation of HIF-1α and a dra-
matic increase in CXCR4 expression due to loss of its abil-
ity to target HIF-1α for degradation by the 26S
proteasome [33,34,44]. In support of these studies, we
demonstrated that either knocking down VHL expression
in SN12C cells (i.e. cells that normally express VHL) or
exposing these cells to hypoxic conditions led to markedly
increased expression of CXCR4 mRNA and protein. Fur-
thermore, our results confirmed that the up-regulation of
CXCR4 expression in RCC induced by these conditions
was mediated by the direct physical interaction between
the HIF-1α transcription factor and its specific binding
sites on the CXCR4 promoter region, which is probably
the hypoxia response element (HRE), as suggested by pre-
vious studies [33,35,45]. This is consistent with our recent
findings in NSCLC, in which the combination of hypoxia
and activation of the tyrosine kinase receptor, EGFR, led
to additive or synergistic up-regulation of CXCR4 expres-
sion via HIF-1α [35]. EGFR activation/signaling and
hypoxia, unlike the VHL mutation, are characteristic of
many cancers. Therefore these findings suggest that tyro-
sine kinase receptor activation and/or a response to
hypoxia, leading to increased HIF-1α, is critical for the
regulation of the expression of CXCR4, and may represent
a general scheme in tumor metastasis.
Since previous studies had found a correlation of CXCR4
expression on metastatic RCC cells, but had not shown a
direct link of CXCL12 and metastasis of CXCR4-express-
ing RCC cells, we then examined whether VHL knock-
down, and subsequently CXCR4 expression, could change
the metastatic potential of these human RCC cell lines in
SCID mice. Our results showed markedly increased
metastases of human RCC cells in an organ-specific man-
ner to adrenal glands, buffy coat, bone marrow, brain,
kidney, spleen, liver and the lungs of mice bearing
SN12C-VHL-KD tumors, as compared to those bearing
SN12C-VC tumors, in both heterotopic and orthotopic
tumor models, using a sensitive analysis of GFP as a
marker of metastatic human cells in murine organs. Most
of these organs have been found to express elevated levels
of CXCL12 in SCID mice [6,7]. Moreover, targeting
CXCL12 with a neutralizing antibody significantly
reduced the metastatic potential of the human RCC cell
lines in the orthotopic model. Therefore, our study pro-
vided initial evidence in an in vivo model system that
directly links the VHL/HIF-1α axis to CXCL12/CXCR4-
mediated organ-specific metastases of human RCC.
CXCL12 is the lone ligand for the chemokine receptor,
CXCR4. Previously it was thought that CXCL12 bound
only to CXCR4. Therefore, targeting of CXCL12 allowed
us to investigate the role of the CXCL12/CXCR4 biological
axis in RCC metastasis in vivo. Moreover, this strategy con-
Table 1: RCC tumor-associated angiogenesis (Factor VIII-related antigen), proliferation (PCNA), and apoptosis (TUNEL) in SCID 
mice treated with anti-CXCL12
Group FVIIIRAA+/hpf PCNA+/hpf TUNEL+/hpf
VC CTRL 9.3 ± 1.3 40.4 ± 6.6 9.2 ± 1.1
VC αCXCL12 6.6 ± 0.8 44.7 ± 3.1 6.7 ± 1.0
p = 0.19 p = 0.60 p = 0.15
KD CTRL 26.7 ± 1.4 107.5 ± 4.8 28.9 ± 2.5
KD αCXCL12 30.1 ± 1.8 116.6 ± 7.6 23.4 ± 3.0
p = 0.13 p = 0.29 p = 0.17
Factor VIII-related antigen stained vessels or PCNA or TUNEL stained cells were counted in 5–10 high power fields (hpf; ×400) in three sections 
from each group. A FVIIIRA: Factor VIII-related antigen. CTRL = control serum. αCXCL12 = specific neutralizing anti-CXCL12 serum.Molecular Cancer 2006, 5:56 http://www.molecular-cancer.com/content/5/1/56
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ferred the advantage of avoiding possible RCC cell clear-
ance from the circulation via antibody-dependent cellular
cytotoxicity, through the use of anti-CXCR4 antibodies.
However, recently it has been reported that CXCL12 is
also a ligand for the orphan receptor RDC1/CXCR7 in T
lymphocytes [46]. Although the distribution and biology
of CXCR7 remains to be elucidated, it is possible that
CXCR7 plays a role in CXCL12-mediated tumor metasta-
sis. If this is indeed the case, then our strategy of targeting
the ligand for both CXCR4 and CXCR7 (CXCL12) allowed
us to block both the biology of CXCR4 and CXCR7 in vivo,
and provided a single-target strategy by which to decrease
the metastatic potential of RCC. Whether our results are
due to inhibiting both CXCR4 and CXCR7 or due solely
to inhibition of CXCR4 remains to be determined.
Although in this study we focused on the effect of VHL
inactivation on CXCL12/CXCR4-mediated organ-specific
metastases, it is possible that other hypoxia-inducible
genes under the control of HIF-1α/VHL pathway may also
play a role in tumor metastasis. Increased HIF-1α has
been shown to regulate a host of genes involved in cellular
processes such as proliferation, survival, glucose metabo-
lism, and angiogenesis [47-50]. For example, vascular
endothelial growth factor (VEGF) has been shown to be
negatively regulated by pVHL [51,52], and its overexpres-
sion is associated with increased tumor angiogenesis and
augmented metastasis in RCC patients [53]. However, we
found that SCID mice bearing orthotopic SN12C-VHL-KD
tumors demonstrated significantly reduced RCC metasta-
sis to specific organs when CXCL12 was depleted by spe-
cific neutralizing antibodies, demonstrating the
importance of CXCL12 biology in mediating tumor
metastasis.
While our data and other studies have suggested the
important role of CXCL12/CXCR4 biological axis in
organ-specific tumor metastasis, studies have also sug-
gested that CXCL12/CXCR4 may be implicated in pro-
moting angiogenesis, tumor cell proliferation and survival
[25-32]. Interestingly, it has been demonstrated that both
RCC cell lines and human RCC tumor specimens express
elevated levels of CXCR4, but not its ligand CXCL12, as
compared to normal kidney specimens [40]. Our findings
demonstrate that tumor-associated angiogenesis, prolifer-
ation and apoptosis are not affected in the primary RCC
tumors in animals treated with neutralizing anti-CXCL12
antibodies, as compared to control antibodies. This is
consistent with our previous study using a NSCLC-bearing
mouse model [7], and indicates that the function of
CXCL12 may not be as important in promoting angiogen-
esis, proliferation, and cell survival in the local tumor
microenvironment of RCC. However, although we see a
significant reduction in the organ-specific metastasis of
RCC cells in response to CXCL12 depletion, we cannot
exclude the possibility that small amounts of non-neutral-
ized CXCL12 remain in the tumor microenvironment and
may contribute to angiogenic and proliferative responses
within the primary tumor.
Conclusion
In conclusion, our studies demonstrate for the first time
the direct link of CXCL12 related to CXCR4-expressing
RCC cells in promoting their metastatic potential. CXCR4
detected on circulating cytokeratin positive cells in
patients with mRCC may represent a biomarker for the
metastatic potential of these cells. Future studies will
determine whether this marker can be used to identify
patients with subclinical metastases. Furthermore, strate-
gies to attenuate the CXCL12/CXCR4 biological axis may
be employed to inhibit the metastatic potential of these
cells in vivo. In fact, small molecule antagonists to CXCR4,
such as AMD3100, and RNA interference strategies have
already been developed to inhibit the binding of lympho-
tropic strains of HIV to CXCR4 on T cells [54-57]. Addi-
tionally, HIF1α antagonists are also in development and
clinical studies are planned in clear cell RCC [58]. There-
fore, in the future, we could see pharmaceutical reagents
used to block the CXCL12/CXCR4 biological axis and
impact on RCC metastasis.
Methods
Reagents
Polyclonal goat anti-CXCL12 antibodies were produced
by immunization with recombinant CXCL12 (PeproTech,
Rocky Hill, NJ) as previously described [7,59]. Five hun-
dred microliters of anti-CXCL12 was sufficient to specifi-
cally neutralize 1 µg of either human or murine CXCL12
in leukocyte chemotaxis assays, and has been found in vivo
to markedly attenuate CXCL12 biology [7,38]. The recom-
binant human chemokine CXCL12 (PeproTech) and neu-
tralizing anti-CXCR4 antibody (R&D Systems,
Minneapolis, MN) were used to assess the proliferation of
human RCC cells in vitro.
Human blood specimens
10 mls of heparinized human blood specimens were
obtained from each of 21 patients with known mRCC and
2 volunteer normal subjects in a pilot study in accordance
with University of California Los Angeles internal review
board approval. Buffy coat cells were isolated from each
blood specimen and analyzed by FACS analysis for cytok-
eratin+, CXCR4+, and dual cytokeratin+ CXCR4+ cells.
Human RCC cell lines
The parental SN12C cell line was originally established in
culture from a surgical specimen of human RCC [60]. We
chose to use SN12C RCC cell line in our current studies
because we have examined the status of the VHL tumor
suppressor gene in the parental SN12C cell line and foundMolecular Cancer 2006, 5:56 http://www.molecular-cancer.com/content/5/1/56
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that intact VHL gene was present in this cell line with no
mutations (data not shown). The SN12C parental cells
(SN12C-P), SN12C cells stably transfected with vector
controls expressing GFP (SN12C-VC), and SN12C-VC
cells stably transfected with a lentiviral deliver system to
express shRNA to knockdown VHL and continue to
express GFP (SN12C-VHL-KD) were generated as previ-
ously described [61].
Heterotopic and orthotopic human RCC-SCID mouse 
chimeras
Six- to eight-week-old female CB17-SCID beige mice
(UCLA Core Facility) were subjected to injection of either
104 SN12C-VHL-KD or SN12C-VC cells into the subcap-
sular region of the left kidney (orthotopic model), or 106
SN12C-VHL-KD or SN12C-VC cells into the flank (heter-
otopic model). Both the SN12C-VHL-KD and SN12C-VC
cells used in this study had been stably transfected with
vectors expressing GFP and had been shown to be GFP+
in 100% of cells by both fluorescence microscopy and
FACS. For CXCL12 depletion studies, tumor-bearing mice
were intraperitoneally injected with either neutralizing
anti-CXCL12, preimmune serum, or received no treat-
ment, using a modification as previously described [7,62-
64]. Mice bearing tumors were sacrificed after 4 weeks,
and their major organs were harvested and processed to
assess single cell suspensions for the expression of GFP by
FACS analysis.
FACS analysis
FACS analysis was performed as previously described
[7,59] using primary antibodies to CXCR4 (R&D Systems)
and pan-cytokeratin; and with secondary antibody Alexa
488 (Molecular Probes, Eugene, OR). For each FACS anal-
ysis, 10,000 events per stained condition were analyzed.
GFP-expressing cells were analyzed directly without stain-
ing.
RNA isolation and Real-Time PCR
Total RNA was isolated with TRIzol (Life Technologies,
Rockville, MD) following manufacturer's instructions as
previously described [7,35,59]. Next, 1.5 µg of RNA was
used and DNase treated to remove contaminating DNA
prior to reverse transcription to cDNA using a ProSTAR
First Strand RT-PCR kit per manufacturer's instructions
(Stratagene). Subsequently, the cDNA was assessed for
changes in CXCR4 expression by real-time PCR using the
ABI Prism 7700 sequence detector and SDS analysis soft-
ware (Applied Biosystems, Foster city, CA) as previously
described [7,35,59].
Hypoxia treatment and whole cell or nuclear extract 
preparation
Hypoxia treatment of SN12C-P, SN12C-VC and SN12C-
VHL-KD cells was performed using a modification as pre-
viously described [35]. Briefly, cells were cultured to a
density of approximately 80% in complete media and
then transferred to starvation media in efforts to synchro-
nize cell cultures. Next, cells were exposed to either nor-
moxia (room air and 5% carbon dioxide) or hypoxia
(94% nitrogen, 5% carbon dioxide and 1% oxygen) in
Modular Incubator Chambers (Billups-Rothenberg, Inc.,
Del Mar CA) for the times indicated. Subsequently, whole
cell extracts (WCE) or nuclear extracts were prepared as
previously described [35]. Briefly, WCE lysis buffer com-
prised 20 mM HEPES pH 7.9, 25% glycerol, 420 mM
NaCl, 1.5 mM MgCl2, and 0.2 mM EDTA, plus a panel of
protease and phosphatase inhibitors (PMSF, DTT, and
NaF at 1 mM; aprotinin, leupeptin, pepstatin, and β-
glcerophophate at10 µg/ml). Buffer for extraction of the
nuclear fraction was composed of 20 mM HEPES, pH 7.9,
400 mM NaCl, and 1 mM EDTA.
Western blotting
Immunoblotting was performed on 40 µg of total protein
from either WCE or nuclear extracts as previously
described [35]. Briefly, following SDS-PAGE, the proteins
were electrophoretically transferred to a PVDF membrane
at 100 V for one hour at room temperature and then
blocked in BLOTTO for 30 minutes. The membranes were
incubated overnight at 4°C with either rabbit anti-human
CXCR4 (1:500; Oncogene Research Products, Cambridge,
MA) or mouse anti-human HIF-1α antibody (1:500; BD
Biosciences). Subsequently, the blots were washed in
TTBS and then incubated with either donkey anti-rabbit
or goat anti-mouse horseradish peroxidase-conjugated
secondary antibodies for 45 minutes at room tempera-
ture. After washing in TTBS (3 times, 15 minutes each
wash), the immunoreactive proteins were finally visual-
ized using ECL Plus following the manufacturer's instruc-
tions (Amersham Biosciences, Piscataway, NJ). To
demonstrate equal loading of protein from WCE, the
membranes were then stripped and reprobed with a
GAPDH antibody (1:500; Abcon).
Tumor cell chemotaxis
SN12C-P, SN12C-VC, and SN12C-VHL-KD cells exposed
to either normoxia or hypoxia for 24 hours were analyzed
for chemotaxis in response to CXCL12 as previously
described [35]. Briefly, cells were harvested by trypsiniza-
tion, counted, and resuspended in RPMI 1640 media con-
taining 10% FCS at a concentration of 106/ml.
Neuroprobe filter (5 µm diameter) pretreated with 5 µg/
ml fibronectin and 12-well chemotaxis chambers were
used for these assays. Recombinant CXCL12 (30 ng/ml;
Peprotech) was added to the lower wells and 1 × 105 cells
were added to each of the upper wells. The chemotaxis
chambers were then incubated for 6 hours at 37°C. After
fixing in methanol and staining in 2% Toluidine blue, the
number of cells that had migrated through to the under-Molecular Cancer 2006, 5:56 http://www.molecular-cancer.com/content/5/1/56
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side of the filters was calculated by counting the total
number of cells in 5 separate fields of view under 400X
magnification.
Chromatin immunoprecipitation assay (ChIP)
SN12C-VC and SN12C-VHL-KD 2 × 106 cells were cul-
tured in 10 ml of starvation media in 100 mm dishes for
24 hours before exposure to either normoxia or hypoxia
for 4 hours. After the exposure, cells were fixed directly by
adding 270 µl of 37% formaldehyde to 10 ml of culture
media and incubating at room temperature for 10 min-
utes. The fixed cells were harvested and prepared for
immunoprecipitation using the protocol of ChIP assay kit
(Upstate Biotechnology Inc., Lake Placid, New York) with
minor modifications. Each sample was precleared with 60
µl of salmon sperm DNA/protein A agarose (Upstate Bio-
technology Inc.). 50 µl of the precleared supernatant from
each sample was taken for later use in PCR analysis to
show total DNA input. One half of each sample was sub-
sequently incubated with either 2 µg of mouse anti-
human HIF-1α antibody (BD Biosciences) or no antibody
at 4°C overnight. Immune complexes were collected with
salmon sperm DNA/protein A-agarose for 1 hour, washed
5 times, and finally eluted in 1% SDS, 0.1 M NaHCO3.
The eluted immune complexes were subsequently reverse
cross-linked and purified by phenol/chloroform extrac-
tion. 10 µl of purified DNA from each sample and DNA
input were used for PCR analysis. PCR analysis was carried
out using primers specific for human CXCR4 promoter
sequences. Sequences of promoter-specific primers
included the CXCR4 promoter region -1860 to -1578 as
follows: sense, 5'-TCGTGCCAAAGCTTGTCCCTG-3'; and
anti-sense, 5'-GCGGTAACCAATTCGCGAATAGTGC-3'.
Transient transfections
SN12C-VC and SN12C-VHL-KD cells were cultured to a
density of 80% in complete media in 12-well plates and
co-transfected with 0.15 µg of a 2.6-kilobase sequence of
the CXCR4 promoter, 0.08 µg of the Renilla control con-
struct (pRL-SV40; Promega, Madison, WI), and 0.08 µg of
a HIF-1α construct as previously described [35]. A GFP
construct was used to equalize the DNA transfection load.
Transfections were performed with Lipofectamine 2000
and Opti-MEM media (Invitrogen, Carlsbad, CA) by fol-
lowing the manufacturer's instructions. The cells were
then cultured for 24 hours at 37 °C before exposure to
normoxia or hypoxia for 8 hours. After the exposure, cell
extracts were made using the luciferase reporter lysis
buffer (Promega). Each lysate was subsequently assayed
in the dual luciferase reporter assay (Promega) following
the manufacturer's instructions; luciferase activity was
determined using a Monolight series 2010 luminometer
(Analytical Luminescence Laboratory) and then normal-
ized to the Renilla control.
Proliferation of human RCC cells in vitro
To assess the in vitro proliferation of human RCC cell
lines, SN12C-VC and SN12C-VHL-KD cells were starved
overnight in serum-free growth medium, trypsinized, and
seeded at a density of 5000 cells/well into 96-well culture
plates containing 1% serum and various concentrations
(1 ng/ml, 3 ng/ml 10 ng/ml, 30 ng/ml or 100 ng/ml) of
CXCL12, or various concentrations (0.5 ug/ml, 2.5 ug/ml
or 10 ug/ml) of neutralizing anti-CXCR4 antibody. The
cells were allowed to grow for 24, 48 or 72 hours. 1 µCi/
well [3H]thymidine was added after the incubation, and
the cultures were incubated for a further 18 hours. Finally,
the cells were harvested using a cell harvester, and
[3H]thymidine incorporation was quantitated by scintilla-
tion counting.
Quantitation of tumor vessel density
Quantitation of tumor vessel density was performed using
a modification as previously described [62]. In brief, tis-
sue sections from tumors of orthotopic human RCC-SCID
mice treated with neutralizing anti-CXCL12 or pre-
immune serum were dewaxed with xylene and rehydrated
through graded concentrations of ethanol. Slides were
stained for endothelial cells using polyclonal antibody to
Factor VIII-related antigen (Biomeda, Foster City, CA).
DAB (Vector Laboratories, Inc., Burlingame, CA) reagent
was used for chromogenic localization of Factor VIII-
related antigen. After optimal color development, sections
were immersed in water and cover-slipped. Tumor speci-
mens were scanned at low magnification (40×) to identify
vascular hot spots. Areas of greatest vessel density were
then examined under higher magnification (200×) and
counted. Any distinct area of positive staining for Factor
VIII-related antigen was counted as a single vessel. Results
were expressed as the number of vessels per high power
field (200×).
Measurement of in vivo apoptosis and proliferation of 
human RCC
Sections of orthotopically injected SN12C-VC and
SN12C-VHL-KD tumors from SCID mice treated with
either control or anti-CXCL12 antibodies were stained
using either the TdT-mediated dUTP nick end labeling
(TUNEL, Roche Applied Science, Indianapolis, IN)
method to detect apoptosis or anti-proliferating cell
nuclear antigen (PCNA, DAKO Corp, Carpinteria, CA) to
detect proliferation, as previously described [62]. Briefly,
cells were counted in high power fields per tumor (400×)
after scanning at low power (40×) to select areas devoid of
frank necrosis. Results were expressed as the number of
apoptotic nuclei per 400X field, or the number of prolifer-
ating (PCNA positive) cells per 400X field. Similarly, in
vitro  apoptosis of SN12C-VC and SN12C-VHL-KD was
studied by plating cells on slide wells with various concen-
trations of CXCL12 (1 ng/ml, 3 ng/ml 10 ng/ml, 30 ng/mlMolecular Cancer 2006, 5:56 http://www.molecular-cancer.com/content/5/1/56
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or 100 ng/ml) or anti-CXCR4 antibody (0.5 ug/ml, 2.5
ug/ml or 10 ug/ml). Cells were stained using the TUNEL
assay, and counted in high power fields (400×).
Statistical analysis
The animal studies involved 6 mice for each treatment
group. Comparisons were evaluated by Student's t test.
Results were presented as means ± SEM. Data were ana-
lyzed using the Statview 5.0 statistical package (Abacus
Concepts, Berkeley, CA). Data were considered statisti-
cally significant if p values were < 0.05.
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